VZV (gE) Peptide Pool
€269.40*
Description
The VZV gE peptide pool is a pool of 153 overlapping peptides derived from a peptide scan through Envelope glycoprotein E (UniProt ID: P09259) of varicella zoster virus (strain Dumas). The 15-mer peptides of the peptide pool overlap by 11 amino acids.
One unit allows the stimulation of 2,5 x 108 cells.
Envelope glycoprotein E of varicella zoster
Envelope glycoprotein E (gE) is the most abundant glycoprotein of the varicella zoster virus (VZV), also known as human herpesvirus 3 (HHV-3). VZV gE is indispensable for the assembly of infectious virions and viral replication. [1] It is highly immunogenic and, therefore, particularly interesting for research and development. VZV gE is recognized as the primary target of varicella-zoster-specific CD4+ T-cell responses, for example. [2]
Application of the VZV gE peptide pool
The VZV gE peptide pool triggers a strong specific T-cells stimulation. Therefore, it is employed in vaccine development, to assess vaccine-induced immunity against the varicella zoster virus. It is also used to investigate the molecular mechanisms behind the pathogenesis of diseases caused by the varicella zoster virus, such as herpes zoster and postherpetic neuralgia. Another application is the investigation of the effect of immunosuppressive therapeutics on immunity against varicella zoster.
Application example
Researchers have used a VZV gE peptide pool to evaluate immunogenicity and memory response in mice induced by mRNA-LNP-based vaccine candidates targeting VZV’s surface glycoprotein E. [3] They stimulated the spleens of the mice with the peptide pool one week after the final immunization. The researchers then measured the percentage of CD8+ and CD4+ T cells producing IFN-γ, TNF-α, and IL-2 by flow cytometry.
The link to the full publications can be found under the References tab.
Read more about the Varicella zoster virus and its proteins in our blog post: "Varicella Zoster Virus: gE, IE-62 and IE-63 essential for Infection"
TechData
| Gene: | gE |
| Delivery: | 1-3 days |
| Counterion: | TFA |
| Length: | 623 amino acids |
| No. Peptides: | 153 peptides |
| Amount/Aliquote: | 15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells |
| Solubility: | Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system. |
| Protein: | Envelope glycoprotein E |
| UniProt Id: | P09259 |
| Species: | Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3) |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response, ELISPOT, ICS, Immune monitoring, Proliferation assay, T-cell expansion |
| Indication: | Infectious disease, Neuroscience |
Documents
References
- Mo, Chengjun et al. “The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.” Virology vol. 304,2 (2002): 176-86. doi:10.1006/viro.2002.1556
- Leroux-Roels, Isabel et al. “A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.” The Journal of infectious diseases vol. 206,8 (2012): 1280-90. doi:10.1093/infdis/jis497
- Bhattacharya, Anannya et al. “Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.” NPJ vaccines vol. 9,1 72. 4 Apr. 2024, doi:10.1038/s41541-024-00865-5
More VZV peptides and peptide pools
